Interphase fluorescence in situ hybridization on selected plasma cells is superior in the detection of cytogenetic aberrations in plasma cell dyscrasia

Genes Chromosomes and Cancer

Volumn 49, Issue 11, 2010, Pages 991-997

  Put, Natalie ^a   Lemmens, Heidi ^a   Wlodarska, Iwona ^a   Konings, Peter ^a   Moreau, Yves ^a   Hagemeijer, Anne ^a   Vandenberghe, Peter ^a   Michaux, Lucienne ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BONE MARROW; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC ANALYSIS; GENETIC DISORDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PLASMA CELL; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; CHROMOSOME ABERRATIONS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERPHASE; MALE; MIDDLE AGED; PARAPROTEINEMIAS;

EID: 77957927156     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20809     Document Type: Article

References (21)

1. Agresti A. 2002. Categorical Data Analysis, 2nd ed. Hoboken, New Jersey: Wiley.
2. Avet-Loiseau H. 2007. Role of genetics in prognostication in myeloma. Best Pract Res Clin Haematol 20:625-635.
3. Avet-Loiseau H, Brigaudeau C, Morineau N, Talmant P, Lai JL, Daviet A, Li JY, Praloran V, Rapp MJ, Harousseau JL, Facon T, Bataille R. 1999. High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization. Genes Chromosomes Cancer 24:9-15.
4. Calasanz MJ, Cigudosa JC, Odero MD, Ferreira C, Ardanaz MT, Fraile A, Carrasco JL, Sole F, Cuesta B, Gullon A. 1997. Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: Primary breakpoints and clinical correlations. Genes Chromosomes Cancer 18:84-93.
5. Chesi M, Bergsagel PL, Shonukan OO, Martelli ML, Brents LA, Chen T, Schrock E, Ried T, Kuehl WM. 1998. Frequent dysregulation of the c-maf protooncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 91:4457-4463.
6. Christensen JH, Abildgaard N, Plesner T, Nibe A, Nielsen O, Sorensen AG, Kerndrup GB. 2007. Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: Analysis of 192 cases from the Region of Southern Denmark. Cancer Genet Cytogenet 174:89-99.
7. Debes-Marun CS, Dewald GW, Bryant S, Picken E, Santana-Davila R, Gonzalez-Paz N, Winkler JM, Kyle RA, Gertz MA, Witzig TE, Dispenzieri A, Lacy MQ, Rajkumar SV, Lust JA, Greipp PR, Fonseca R. 2003. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 17:427-436.
8. Dewald GW, Kyle RA, Hicks GA, Greipp PR. 1985. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 66:380-390.
9. Fay MP. 2010. Confidence intervals that match Fischer's exact or Blaker's exact tests. Biostat 11:373-374.
10. Fiserova A, Hajek R, Holubova V, Buchler T, Sobotka J, Kovarova R, Musilova R, Bourkova L, Bulikova A, Mareschova I, Janackova Z, Vanova P, Kuglik P, Vorlicek J, Penka M. 2002. Detection of 13q abnormalities in multiple myeloma using immunomagnetically selected plasma cells. Neoplasma 49:300-306.
11. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, Dewald GW, Van Ness B, Van Wier SA, Henderson KJ, Bailey RJ, Greipp PR. 2003. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101:4569-4575.
12. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, Davies FE, Drach J, Greipp PR, Kirsch IR, Kuehl WM, Hernandez JM, Minvielle S, Pilarski LM, Shaughnessy JD, Jr., Stewart AK, Avet-Loiseau H. 2004. Genetics and cytogenetics of multiple myeloma: A workshop report. Cancer Res 64:1546-1558.
13. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, Morgan G, Van Ness B, Chesi M, Minvielle S, Neri A, Barlogie B, Kuehl WM, Liebisch P, Davies F, Chen-Kiang S, Durie BG, Carrasco R, Sezer O, Reiman T, Pilarski L, Avet-Loiseau H. 2009. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 23:2210-2221.
14. Lai JL, Zandecki M, Mary JY, Bernardi F, Izydorczyk V, Flactif M, Morel P, Jouet JP, Bauters F, Facon T. 1995. Improved cytogenetics in multiple myeloma: A study of 151 patients including 117 patients at diagnosis. Blood 85:2490-2497.
15. Liebisch P, Döhner H. 2006. Cytogenetics and molecular cytogenetics in multiple myeloma. Eur J Cancer 42:1520-1529.
16. McNemar Q. 1947. Note on the sampling error of the difference between correlated proportions or percentages. Psychometrika 12:153-157.
17. Rajkumar SV, Buadi F. 2007. Multiple myeloma: New staging systems for diagnosis, prognosis and response evaluation. Best Pract Res Clin Haematol 20:665-680.
18. Sawyer JR, Waldron JA, Jagannath S, Barlogie B. 1995. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 82:41-49.
19. Sirohi B, Powles R. 2006. Epidemiology and outcomes research for MGUS, myeloma and amyloidosis. Eur J Cancer 42:1671-1683.
20. Weh HJ, Gutensohn K, Selbach J, Kruse R, Wacker-Backhaus G, Seeger D, Fiedler W, Fett W, Hossfeld DK. 1993. Karyotype in multiple myeloma and plasma cell leukaemia. Eur J Cancer 29A:1269-1273.
21. Zojer N, Konigsberg R, Ackermann J, Fritz E, Dallinger S, Kromer E, Kaufmann H, Riedl L, Gisslinger H, Schreiber S, Heinz R, Ludwig H, Huber H, Drach J. 2000. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 95:1925-1930.